Sunday, November 22, 2026
20 C
Bengaluru

Kailash Joshi has been appointed as Executive Director – Analytics, Insights & Decision Enablement (US) at Novartis, as part of the Novartis Global Capability Center in Hyderabad.

With extensive experience across commercial excellence, analytics, insights, AI-driven decision-making, and healthcare strategy, Kailash brings a strong track record of enabling organizations to leverage data and technology to drive better business outcomes.

In his new role, he will lead a team of professionals and subject matter experts within the Novartis US Analytics, Insights & Decision Enablement organization. His focus will be on harnessing the power of analytics, insights, and emerging technologies to transform data into actionable intelligence and support strategic decision-making.

Kailash returns to Novartis with a wealth of experience in commercial strategy and healthcare transformation. His leadership journey includes driving initiatives across commercial excellence, customer engagement, business intelligence, omnichannel strategy, and capability building.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img